Dr. Dongyang Liu is now a professor and director of the Clinical Pharmacology and Pharmacometrics Office (CPPO) and deputy director of Drug Clinical Trial Center of Peking University Third Hospital (PUTH). Up to now, he has been responsible for clinical trials or MiDD studies of more than 50 novel drugs as PI and has published more than 60 international peered articles, such as Acta pharmaceutica Sinica B, EClinicalMedicine, Clin Pharmacokinet, and Clin Infect Dis, as the first or corresponding author. He was invited to be the vice chairman of the Professional Committee of Pharmacometrics and a committeeman of Professional Clinical Pharmacology in Chinese Pharmacological Society, as well as the Associate Editor of BDD and Editor of the JPKPD journal. He earned a National Innovation Competition Award (Rank Six). Currently, he is majorly interested in 1) the early-phase clinical development for new drugs; 2) PBPK-PD-Disease model research for new drug development and precision dosing.